T helper cell-mediated interferon-gamma expression after human parvovirus B19 infection: Persisting VP2-specific and transient VP1u-specific activity

Clinical and Experimental Immunology

Volumn 142, Issue 1, 2005, Pages 53-61

  Franssila, Rauli ^a   Auramo, J ^a   Modrow, S ^c   Mobs M ^c   Oker Blom, C ^b   Kapyla P ^b   Soderlund Venermo M ^a   Hedman, K ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF JYVÄSKYLÄ   (Finland)

^c UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Human parvovirus B19; Memory; Pregnancy; Prolonged symptoms; Th cell; Vaccine

Indexed keywords

GAMMA INTERFERON; HLA ANTIGEN CLASS 2; INTERLEUKIN 10; PROTEIN VP1U; PROTEIN VP2; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADULT; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; ERYTHEMA INFECTIOSUM; EUKARYOTE; FEMALE; HELPER CELL; HUMAN; MALE; PARVOVIRUS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; CAPSID PROTEINS; CELL DIVISION; CELLS, CULTURED; ENDOTOXINS; EPITOPES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNITY, CELLULAR; INTERFERON TYPE II; INTERLEUKIN-10; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 25444469969     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2005.02886.x     Document Type: Article

References (50)

1. Bansal GP, Hatfield JA, Dunn FE et al. Candidate recombinant vaccine for human B19 parvovirus. J Infect Dis 1993; 167:1034-44.
2. Rosenfeld SJ, Yoshimoto K, Kajigaya S et al. Unique region of the minor capsid protein human parvovirus B19 is exposed on the virion surface. J Clin Invest 1992; 89:2023-9.
3. Heegaard ED, Brown KE. Human parvovirus B19. Clin Microbiol Rev 2002; 15:485-505.
4. Chorba T, Coccia P, Holman RC et al. The role of parvovirus B19 in aplastic crisis and erythema infectiosum (fifth disease). J Infect Dis 1986; 154:383-93.
5. Kerr JR, Mattey DL, Thomson W et al. Association of symptomatic acute human parvovirus B19 infection with human leukocyte antigen class I and II alleles. J Infect Dis 2002; 186:447-52.
6. Anderson MJ, Lewis E, Kidd IM et al. An outbreak of erythema infectiosum associated with human parvovirus infection. J Hyg Camb 1984; 9:85-93.
7. White DG, Mortimer PP, Blake DR et al. Human parvovirus arthropathy. Lancet 1985; 1:419-21.
8. Saarinen UM, Chorba TL, Tattersall P et al. Human parvovirus B19-induced epidemic acute red cell aplasia in patients with hereditary hemolytic anemia. Blood 1986; 6:1411-7.
9. Kurtzman GJ, Cohen BJ, Field AM et al. Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest 1989; 84:1114-23.
10. Faden H, Gary GW, Anderson LJ. Chronic parvovirus infection in a presumably immunologically healthy woman. Clin Infect Dis 1992; 15:595-7.
11. Söderlund M, von Essen R, Haapasaari J et al. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet 1997; 349:1063-5.
12. Foto F, Saag KG, Scharosch LL et al. Parvovirus B19-specific DNA in bone marrow from B19 arthropathy patients: evidence for B19 virus persistence. J Infect Dis 1993; 167:744-8.
13. Takahashi Y, Murai C, Shibata S et al. Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci USA 1998; 95:8227-32.
14. Anand A, Gray ES, Brown T et al. Human parvovirus infection in pregnancy and hydrops fetalis. N Engl J Med 1987; 316:183-7.
15. Tolfvenstam T, Papadogiannikis N, Norbeck O et al. Frequency of human parvovirus Bl9 infection in intrauterine fetal death. Lancet 2001; 357:1494-7.
16. Nikkari S, Lappalainen H, Saario R et al. Detection of parvovirus B19 in skin biopsy, serum and bone marrow of a patient with fever, rash and polyarthritis followed by pneumonia, pericardial effusion and hepatitis. Eur J Clin Microbiol Infect Dis 1996; 15:954-7.
17. Franssila R, Hokynar K, Hedman K. T helper cell-mediated in vitro responses of recently and remotely infected subjects to a candidate recombinant vaccine for human parvovirus B19. J Infect Dis 2001; 183:805-9.
18. Nakazawa T, Machi T, Kitagawa S et al. Parvovirus infection and generalized edema in adults. Intern Med 1995; 34:163-5.
19. Ballou WR, Reed JL, Noble W et al. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J Infect Dis 2003; 187:675-8.
20. Franssila R, Hedman K. T-helper cell mediated interferon-gamma, interleukin 10 and proliferation responses to a candidate recombinant vaccine for human parvovirus B19. Vaccine 2004; 22:3809-15.
21. Spellberg B, Edwards JE. Type 1/type 2 immunity in infectious diseases. Clin Infect Dis 2001; 32:76-102.
22. Hughes T, Baron S. Do the IFNs act singly or in combination? J Interferon Res 1987; 7:603-14.
23. + T cell clones and resting T cells. J Immunol 1993; 150:4754-65.
24. Brière F, Servet-Delprat C, Bridon JM et al. Human interleukin 10 induces naïve surface immunoglobulin D+ (sIgD+) B cells to secrete IgG1 and IgG3. J Exp Med 1994; 179:757-62.
25. Franssila R, Söderlund M, Brown CS et al. IgG subclass response to human parvovirus B19 infection. Clin Diagn Virol 1996; 6:41-9.
26. Corcoran A, Doyle S, Waldron D et al. Impaired gamma interferon responses against parvovirus B19 by recently infected children. J Virol 2000; 74:9903-10.
27. Kawano Y, Noma T, Yata J. Regulation of human IgG subclass production by cytokines. J Immunol 1994; 153:4948-58.
28. Kaikkonen L, Lankinen H, Harjunpää I et al. Acute-phase-specific heptapeptide epitope for diagnosis of parvovirus B19 infection. J Clin Microbiol 1999; 3:3952-6.
29. Von Poblotzki A, Gerdes C, Reischl U et al. Lymphoproliferative responses after infection with human parvovirus B19. J Virol 1996; 70:7327-30.
30. De Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes. An autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174:1209-20.
31. Bluth MH, Norowitz KB, Chice S et al. Detection of IgE antiparvovirus B19 and increased CD23+ B cells in parvovirus B19 infection: relation to Th2 cytokines. Clin Immunol 2003; 108:152-8.
32. Wagner A, Goronzy J, Matteson E et al. Systemic monocyte and T-cell activation in a patient with human parvovirus B19 infection. Mayo Clin Proc 1995; 70:261-5.
33. Kerr JR, Barah F, Mattey DL et al. Circulating tumor necrosis factor-α and interferon-γ are detectable during acute and convalescent parvovirus B19 infection and are associated with prolonged and chronic fatigue. J Gen Virol 2001; 82:3011-9.
34. Kerr JR, Barah F, Chiswick ML et al. Evidence for the role of demyelination, HLA-DR alleles, and cytokines in the pathogenesis of parvovirus B19 meningoencephalitis and its sequelae. J Neurol Neurosurg Psychiatry 2002; 73:739-46.
35. Nigro G, Bastianon V, Colloridi V et al. Human parvovirus B19 infection in infancy associated with acute and chronic lymphocytic myocarditis and high cytokine levels: report of 3 cases and review. Clin Infect Dis 2000; 3:65-9.
36. Mitchell LA, Leong R, Rosenke KA. Lymphocyte recognition of human parvovirus B19 non-structural (NS1) protein: associations with occurrence of acute and chronic arthropathy. J Med Microbiol 2001; 50:627-35.
37. + subsets. J Immunol 1995; 155:3322-8.
38. Mehraein Y, Lennerz C, Ehlhardt S et al. Detection of parvovirus B19 capsid proteins in lymphocytic cells in synovial tissue of autoimmune chronic arthritis. Mod Pathol 2002; 16:811-7.
39. Saal JG, Steidle M, Einsele H et al. Persistence of B19 parvovirus in synovial membranes of patients with rheumatoid arthritis. Rheumatol Int 1992; 12:147-51.
40. Lehmann HW, Knöll A, Küster R-M et al. Frequent infection with a viral pathogen, parvovirus B19, in rheumatic diseases of childhood. Arthritis Rheum 2003; 48:1631-8.
41. Lunardi C, Tiso M, Borgato L et al. Chronic parvovirus B19 infection induces the production of anti-virus antibodies with autoantigen binding properties. Eur J Immunol 1998; 28:936-48.
42. Raghupathy R. Pregnancy: success and failure within the Th1/Th2/Th3 paradigm. Semin Immunol 2001; 13:219-27.
43. Corcoran A, Mahon B, McParland P et al. Ex vivo cytokine responses against parvovirus B19 antigens in previously infected pregnant women. J Med Virol 2003; 70:475-80.
44. Marzi M, Vigano A, Trabattoni D et al. Characterization of type 1 and type 2 cytokine production profile in physiologic and pathologic human pregnancy. Clin Exp Immunol 1996; 106:127-33.
45. McKisic MD, Paturzo FX, Gaertner DJ et al. A nonlethal rat parvovirus infection suppresses rat T lymphocyte effector functions. J Immunol 1995; 155:3979-86.
46. Söderlund M, Brown CS, Spaan WJM et al. Epitope type-specific IgG responses to capsid proteins VP1 and VP2 of human parvovirus B19. J Infect Dis 1995; 172:1431-6.
47. Simitsek PD, Campbell DG, Lanzavecchia A et al. Modulation of antigen processing by bound antibodies can boost or suppress calss II major histocompatibility complex presentation of different T cell determinants. J Exp Med 1995; 181:1957-63.
48. Del Prete GF, De Carli M, Ricci M et al. Helper activity for immunoglobulin synthesis of T helper type 1 (Th1) and Th2 human T cell clones: the help of Th1 clones is limited by their cytolytic capacity. J Exp Med 1991; 174:809-13.
49. Ahmed R, Gray D. Immunological memory and protective immunity: understanding their relation. Science 1996; 272:54-60.
50. McGuirk P, Mills KHG. Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious diseases. Trends Immunol 2002; 23:450-5.